Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning (RIC) With Post-Transplant Cytoxan (PTCy) for the Treatment of Hematological Diseases
This study tests a special type of stem cell transplant using a milder conditioning treatment and helpful medications to prevent rejection. It aims to help patients with various blood cancers and bone marrow disorders replace diseased cells with healthy ones safely.
Patients aged 0 to 75 with certain blood cancers or bone marrow disorders in remission may qualify, provided they have a suitable donor and meet specific health standards. Pregnant individuals or those with untreated infections or active brain cancer cannot join.
Participants will receive gentle chemotherapy and whole-body radiation to prepare their bodies, followed by healthy stem cell infusions from a donor. Afterward, they will take specific medications to help their bodies accept the new cells and prevent complications.
This study is currently recruiting participants and takes place in Minneapolis, Minnesota, United States.
- 1Evaluates a gentler conditioning approach for stem cell transplants
- 2Open to patients up to 75 years old with compatible donors
- 3Uses specialized medications to prevent transplant rejection
Related links
Outside pages about this study, checked by our team
This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.